Open AccessOral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis
Author(s) -
Aparna Sharma,
Prabhat Singh Malik,
Sachin Khurana,
Sunesh Kumar,
Neerja Bhatla,
M. D. Ray,
Lalit Kumar
Publication year - 2019
Publication title -
indian journal of medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.578
H-Index - 87
ISSN - 0971-5916
DOI - 10.4103/ijmr.ijmr_2030_18
Subject(s) - medicine , chemotherapy , regimen , common terminology criteria for adverse events , refractory (planetary science) , progression free survival , adverse effect , epithelial ovarian cancer , surgery , gastroenterology , cancer , ovarian cancer , oncology , physics , astrobiology
Advanced epithelial ovarian cancer (EOC) is associated with dismal outcome and progression-free survival (PFS) shortens with each subsequent relapse. For patients with recurrent and platinum refractory disease, therapeutic options are limited. Oral metronomic therapy (OMT) is associated with symptomatic relief and stable response in a significant proportion of patients. We retrospectively evaluated the outcome of patients with EOC treated with OMT at a tertiary care hospital in north India.